These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

401 related articles for article (PubMed ID: 22987850)

  • 1. NMDA receptor and schizophrenia: a brief history.
    Coyle JT
    Schizophr Bull; 2012 Sep; 38(5):920-6. PubMed ID: 22987850
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Twenty-five years of glutamate in schizophrenia: are we there yet?
    Javitt DC
    Schizophr Bull; 2012 Sep; 38(5):911-3. PubMed ID: 22987849
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Capturing the angel in "angel dust": twenty years of translational neuroscience studies of NMDA receptor antagonists in animals and humans.
    Moghaddam B; Krystal JH
    Schizophr Bull; 2012 Sep; 38(5):942-9. PubMed ID: 22899397
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Glutamate and schizophrenia: phencyclidine, N-methyl-D-aspartate receptors, and dopamine-glutamate interactions.
    Javitt DC
    Int Rev Neurobiol; 2007; 78():69-108. PubMed ID: 17349858
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Converging evidence of NMDA receptor hypofunction in the pathophysiology of schizophrenia.
    Coyle JT; Tsai G; Goff D
    Ann N Y Acad Sci; 2003 Nov; 1003():318-27. PubMed ID: 14684455
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [NMDA-type glutamate receptor and schizophrenia].
    Nishikawa T; Ishiwata S
    Nihon Shinkei Seishin Yakurigaku Zasshi; 2013 Nov; 33(5-6):217-24. PubMed ID: 25069261
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Glutamatergic mechanisms in schizophrenia.
    Tsai G; Coyle JT
    Annu Rev Pharmacol Toxicol; 2002; 42():165-79. PubMed ID: 11807169
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phencyclidine/schizophrenia: one view toward the past, the other to the future.
    Domino EF; Luby ED
    Schizophr Bull; 2012 Sep; 38(5):914-9. PubMed ID: 22390879
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Glutamatergic synaptic dysregulation in schizophrenia: therapeutic implications.
    Coyle JT; Basu A; Benneyworth M; Balu D; Konopaske G
    Handb Exp Pharmacol; 2012; (213):267-95. PubMed ID: 23027419
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of paliperidone and risperidone on extracellular glutamate in the prefrontal cortex of rats exposed to prenatal immune activation or MK-801.
    Roenker NL; Gudelsky G; Ahlbrand R; Bronson SL; Kern JR; Waterman H; Richtand NM
    Neurosci Lett; 2011 Aug; 500(3):167-71. PubMed ID: 21699956
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Glutamate and schizophrenia: beyond the dopamine hypothesis.
    Coyle JT
    Cell Mol Neurobiol; 2006; 26(4-6):365-84. PubMed ID: 16773445
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Glutaminergic hypothesis of schizophrenia: clinical research studies with ketamine].
    Mechri A; Saoud M; Khiari G; d'Amato T; Dalery J; Gaha L
    Encephale; 2001; 27(1):53-9. PubMed ID: 11294039
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Substance use disorders and Schizophrenia: a question of shared glutamatergic mechanisms.
    Coyle JT
    Neurotox Res; 2006 Dec; 10(3-4):221-33. PubMed ID: 17197372
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy of a glycine transporter 1 inhibitor TASP0315003 in animal models of cognitive dysfunction and negative symptoms of schizophrenia.
    Chaki S; Shimazaki T; Karasawa J; Aoki T; Kaku A; Iijima M; Kambe D; Yamamoto S; Kawakita Y; Shibata T; Abe K; Okubo T; Sekiguchi Y; Okuyama S
    Psychopharmacology (Berl); 2015 Aug; 232(15):2849-61. PubMed ID: 25869273
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Schizophrenia: Basic and Clinical.
    Coyle JT
    Adv Neurobiol; 2017; 15():255-280. PubMed ID: 28674984
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Schizophrenia, dissociative anaesthesia and near-death experience; three events meeting at the NMDA receptor.
    Bonta IL
    Med Hypotheses; 2004; 62(1):23-8. PubMed ID: 14729000
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Progress towards validating the NMDA receptor hypofunction hypothesis of schizophrenia.
    Lindsley CW; Shipe WD; Wolkenberg SE; Theberge CR; Williams DL; Sur C; Kinney GG
    Curr Top Med Chem; 2006; 6(8):771-85. PubMed ID: 16719816
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Animal model of schizophrenia: dysfunction of NMDA receptor-signaling in mice following withdrawal from repeated administration of phencyclidine.
    Nabeshima T; Mouri A; Murai R; Noda Y
    Ann N Y Acad Sci; 2006 Nov; 1086():160-8. PubMed ID: 17185514
    [TBL] [Abstract][Full Text] [Related]  

  • 19. N-Methyl-D-aspartate receptors as a target for improved antipsychotic agents: novel insights and clinical perspectives.
    Millan MJ
    Psychopharmacology (Berl); 2005 Apr; 179(1):30-53. PubMed ID: 15761697
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Has an angel shown the way? Etiological and therapeutic implications of the PCP/NMDA model of schizophrenia.
    Javitt DC; Zukin SR; Heresco-Levy U; Umbricht D
    Schizophr Bull; 2012 Sep; 38(5):958-66. PubMed ID: 22987851
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.